Dermatology
| Urticaria
Dermatology
Urticaria
Efficacy and safety of ligelizumab in patients with chronic spontaneous urticaria: Results of two Phase 3 randomized controlled trials
book_2
Source:
EADV Congress 2022 - Oral session
calendar_today
Published on Medfyle:
September 2022
import_contacts
7
min
headphones
5
min
In this medfyle
Data from the Phase 3 PEARL studies in CSU suggest ligelizumab – a next-generation anti-IgE ¬may offer an additional treatment option.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a highlights summary of an oral session given at the EADV 2022 - 31st Congress and presented by:
Professor Marcus Maurer
UCARE Institute of Allergology
Charité – Universitätsmedizin
Berlin, Germany
The content is produced by Infomedica, the official reporting partner of EADV 2022.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
